Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics

Paneesha, Shankaranarayana; McManus, Aidan; Arya, Roopen; Scriven, Nicholas; Farren, Timothy; Nokes, Timothy J.; Bacon, Sue; Nieland, Anthea; Cooper, Derek; Smith, Harry; O’Shaughnessy, Denise; Rose, Peter; Investigators, Verity

doi:10.1160/th09-06-0397

Cited by 87 publications

(73 citation statements)

References 20 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast cancer-associated VTE accounts for approximately 17% of cancerrelated VTEs presenting to anticoagulation clinics. 4 It is also associated with increased disease recurrence, 5 but more importantly, reduced survival 5,6 among patients for whom prognosis is otherwise comparatively good.…”

Section: Introductionmentioning

confidence: 99%

When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data

Walker

West

Card

et al. 2016

Blood

100

View full text Add to dashboard Cite

Key Points• Patients with breast cancer have a risk of VTE equivalent to 6% a year while undergoing chemotherapy and in the month after treatment.• Tamoxifen is associated with a risk of VTE equivalent to 2% a year, which is 4 times higher than the risk before starting therapy.Patients with breast cancer are at increased risk of venous thromboembolism (VTE), particularly in the peridiagnosis period. However, no previous epidemiologic studies have investigated the relative impact of breast cancer treatments in a time-dependent manner. We aimed to determine the impact of breast cancer stage, biology, and treatment on the absolute and relative risks of VTE by using several recently linked data sources from England. .6 per 1000 person-years) than that in women who did not receive chemotherapy. After surgery, the risk was significantly increased in the first month (hazard ratio [HR], 2.2; 95% CI, 1.4-3.4; AR, 23.5; reference group, no surgery), but the risk was not increased after the first month. Risk of VTE was noticeably higher in the 3 months after initiation of tamoxifen compared with the risk before therapy (HR, 5.5; 95% CI, 2.3-12.7; AR, 24.1); however, initiating therapy with aromatase inhibitors was not associated with VTE (HR, 0.8; 95% CI, 0.5-1.4; AR, 28.3). In conclusion, women receiving chemotherapy for breast cancer have a clinically important risk of VTE, whereas an increased risk of VTE immediately after endocrine therapy is restricted to tamoxifen. (Blood. 2016;127(7):849-857) Medscape Continuing Medical Education onlineThis activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medscape, LLC and the American Society of Hematology. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/blood; and (4) view/print certificate. For CME questions, see page 953. Disclosures Thomas L. Ortel, Associate Editor, served as an advisor or consultant for Instrumentation Laboratory and received grants for clinical research from Instrumentation Laboratory; Eisai; Pfizer; and GlaxoSmithKline. The authors and CME questions author Laurie Barclay, freelance writer and reviewer, Medscape, LLC, declare no competing financial interests. Learning objectives1. Identify the effect of chemotherapy for breast cancer on the risk for venous thromboembolism, based on an English cohort study.2. Determi...

show abstract

Section: Introductionmentioning

confidence: 99%

When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data

Walker

West

Card

et al. 2016

Blood

100

View full text Add to dashboard Cite

show abstract

“…Clinically, tumor neutrophil infiltration is associated with poor metastasis and prognosis, mainly in renal cancer, melanoma, liver cancer, colorectal cancer, lung cancer, and head and neck cancer [12,13]. Wang et al found that neutrophil infiltration in squamous cell carcinoma of the tongue is associated with lymph node metastasis, clinical stage, and increased tumor recurrence risk [14].…”

Section: The Possible Role Of Neutrophils In Liquid Biopsymentioning

confidence: 99%

Progress in Liquid Biopsy: A possible role of neutrophils

Liang¹,

Yu²

2018

View full text Add to dashboard Cite

show abstract

“…Panessha et al 20 reported that the rate of cancer-related VTE managed in outpatient DVT clinics in the UK for AYAs between 18 and 31 was 2.6%. Kayser-Gatchalian and Kayser 21 reported a higher incidence of VTE for patients aged 20-39 years with intracranial tumors compared to those aged 10-19 years.…”

Section: Epidemiologymentioning

confidence: 99%

Optimal management of venous thromboembolism in adolescent and young adult oncology patients

Brandwein¹,

McKillop²,

Wu³

et al. 2016

COAYA

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a serious complication experienced by adolescents and young adults (AYAs) diagnosed with cancer. Data exist in the adult literature to guide the management of cancer-associated thrombosis. Unfortunately, little is known regarding the epidemiology of cancer-associated thrombosis in AYAs. As a result, evidence on the treatment and prevention of thrombosis in this vulnerable population is lacking, posing a great challenge to physicians caring for AYAs with cancer. It is clear that the basic principles of VTE likely apply to AYAs and that low-molecular-weight heparin is the drug of choice for the treatment of VTE regardless of age. We review the available data on the epidemiology, diagnostic methods, and management of AYAs with cancer and VTE. Recognizing the lack of accepted guidelines for the prevention or management of VTE in this population, we offer expert opinion recommendations to serve as guidance to improve management of thrombosis in AYA cancer patients.

show abstract

Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics

Cited by 87 publications

References 20 publications

When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data

When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data

Progress in Liquid Biopsy: A possible role of neutrophils

Optimal management of venous thromboembolism in adolescent and young adult oncology patients

Contact Info

Product

Resources

About